Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 PM ET. CEO Jeffrey F. Eisenberg will deliver the presentation in Miami, FL, and virtually. The management team will also be available for one-on-one meetings with investors. A live video webcast will be accessible on the Company's website and archived for 90 days. Xenetic is advancing therapies targeting Neutrophil Extracellular Traps and developing CAR T platform technology.
Details
News Market Reaction – XBIO
The recorded move for XBIO in the trading session of this news was -1.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET
FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C. Wainwright Global Investment Conference being held in Miami, FL and virtually on Wednesday, May 25, 2022 at 4:00 PM ET.
In addition to the presentation, members of the management team will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A live video webcast of the presentation will be available on the Events page in the Investors section of the Company's website (xeneticbio.com) and archived for 90 days following the event.
For more information about the conference, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications. The Company's DNase oncology platform, in development for the treatment of solid tumors, is aimed at improving outcomes of existing treatments, including immunotherapies, by targeting Neutrophil Extracellular Traps (NETs). The Company is also developing its personalized CAR T platform technology, XCART™, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, to partner with biotechnology and pharmaceutical companies. PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company receives royalty payments under an exclusive license arrangement in the field of blood coagulation disorders.
For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/701815/Xenetic-Biosciences-Inc-to-Present-at-the-HC-Wainwright-Global-Investment-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.